Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,025 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous arm Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

NCT01308541
View directory record Official record
Conditions
Monitored Anesthesia Care
Interventions
arm 1, LUSEDRA, Propofol (arm 3)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City Utah, Utah
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

NCT07104331
View directory record Official record
Conditions
Epithelioid Hemangioendothelioma (EHE)
Interventions
nab-Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

NCT00179309
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, PANVAC-V, PANVAC-F, Sargramostim
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NCT05469893
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Teclistamab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Irene Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

NCT04393298
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ginisortamab, trifluridine/tipiracil, mFOLFOX6
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 6, 2026, 5:41 PM EDT
Withdrawn Phase 3 Interventional

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

NCT02196207
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab, Eloctate ITI
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
4 Months to 99 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 6, 2026, 5:41 PM EDT
Not listed Phase 2 Interventional

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

NCT03719664
View directory record Official record
Conditions
HIV-1-infection
Interventions
Albuvirtide, 3BNC117, Baseline ART
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 6, 2026, 5:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

NCT04570384
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
L-Citrulline, Placebo
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

NCT04593121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB107, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 6, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

NCT04299880
View directory record Official record
Conditions
Oncology
Interventions
Napabucasin, Nab-paclitaxel, Gemcitabine, Nivolumab, Paclitaxel, Irinotecan, Leucovorin, 5Fluorouracil, Bevacizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Scarborough, Maine • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

NCT06904378
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ONT01, Gemcitabine, Nab paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT07337525
View directory record Official record
Conditions
Advanced Malignant Solid Tumor, Solid Tumor Cancer
Interventions
PLT012
Drug
Lead sponsor
Pilatus Biosciences Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05315713
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Follicular Lymphoma
Interventions
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

NCT02468674
View directory record Official record
Conditions
Sarcopenia
Interventions
bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 6, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Refrigerant to Reduce the Pain Associated With IV Insertion

NCT02499965
View directory record Official record
Conditions
Pain
Interventions
Ethyl Chloride Topical Aerosol Anesthetic, Nature's Tears Sterile Water
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

NCT01629758
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 6, 2026, 5:41 PM EDT